Home About us Products Raw Material Peptides R&D Center Contact us
    Position > Products  
Nomatropin HGH
IGF-1 Long R3
GHRP-6
Follistatin 344
CJC1295
Nomad H.C.G 5000
Bold 300
Bold 300 Amp.
DECA 100
DECA 100 Amp.
Deca 300
Deca 300 Amp.
Depot Cyp 250
Depot Cyp 250 Amp.
Aqua Test
Aqua Test Amp.
Nomasteron 100
Nomasteron 100 Amp.
Nomasteron 200
Nomasust 250
Nomasust 250 Amp.
Nomaviron 300
Nomaviron 300 Amp.
Prop 100
Prop 100 Amp.
Stanazol 50
Stanazol 50 Amp.
Tren 100 Short
Tren 100 Short Amp.
Tren 100 Mix
Tren 100 Mix Amp.
Tren 200 Long
Nomatest Combo 300
Nomatest Combo 300
Amp.
Primo 100
Primo 100 Amp.
Dianabol Tab.
Anavar Tab.
Stanazolol Tab.
Anadrol Tab.
Cytomel 25 Tab.
Halotestin Tab.
Clen 40 Tab.
Arimidex Tab.
Provi 25 Tab.
 
Details
 
 
 
 
 
Products  
 
CJC1295 Model:

CJC1295 is a Long-acting growth-hormone-releasing hormone (GHRH) analog. Because of the long half-life and stability of the CJC1295 analog, it appears to become more and more popular. CJC1295 is a Long acting GHRH analog. Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF or GHRF) or somatocrinin, is a 44-amino acid peptide hormone produced in the hypothalamus by the arcuate nucleus. GHRH stimulates growth hormone (GH) secretion from the pituitary. GHRH is released in a pulsatile manner, stimulating pulsatile release of GH respectively. In addition, GHRH also promotes slow-wave sleep.

 
Details

The active portion of this GRF or GHRH peptide can be found as a 29 amino acid long peptide and is appropriately named GHRH1-29. This pulsatile release of various peptides is due to the negative feedback loop that is part of the hGH axis and controls the amount of hGH that your body produces to keep it in a homeostatic environment. Despite the effectiveness of GHRH to stimulate growth hormone release there are a number of problems associated with using it in vivo. The most noteworthy problem is the half life of the peptide, which has been shown to be ~7 minutes using advanced HPLC technologies that have proven to be very accurate. The reason for this relatively short half life is due to an enzyme called dipeptidylaminopeptidase IV (DPP-IV), which has a high affinity for the amino acids Ala and Pro and in the case of GHRH it cleaves the 1 and 2 positions that consist of Tyr-Ala, creating GHRH3-29, an inactive form of the peptide. To prevent the problems associated with natural GHRH, pharmaceutical companies looked at new ways to increase the half life and bioavailability of these smaller peptides with technologies that work far different than other technologies, such as Pegylation.

CJC1295 is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation. By applying the Drug Affinity Complex (DAC) technology to GRF, the peptide selectively and covalently binds to circulating albumin after subcutaneous (SC) administration, thus prolonging its half-life. These substitutions are key in increasing the overall half life of CJC1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days!

Bioconjugation is a relatively newer technology that takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucelophile by this particular peptide thanks to a Cys34 thiol group that attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity for albumin. Once the CJC1295 molecule has attached itself to albumin, it is given an extended half life and bioavailability thanks to the albumin preventing enzymatic degredation and kidney excretion. In fact, bioconjugation is so effective that there was less than 1% of CJC1295 left unreacted in vivo and over 90% was stabilized after subcutaneous injection. This means that you get more of what you paid for working for you. There was no DPP-IV degredation observed on CJC1295 in any of the various experiments conducted.

 
Print Back
   
| Home | About us | Products | R&D Center | Contact us
Copyright © 2011 NomadLab Biomedical Engineering Co., Limited. All Rights Reserved
Design By RGBnet.com